Mallinckrodt Pharmaceuticals announced this week that the company expects to pay $15.4 million in a settlement with the U.S. Justice Department after allegations that Questcor Pharmaceuticals, which Mallinckrodt acquired in 2014, had bribed doctors and their staff to prescribe an incredibly expensive drug. From a report: Two whistleblowers came forward in April to accuse Questcor of trying to boost profits for Acthar, a medication primarily for infants with seizures. Questcor raised the price of the medication by almost 100,000 percent (not a typo) from just $40 in 2000 to $38,892 today, despite the fact that Acthar has been on the market since 1952. Mallinckrodt currently rakes in about $1 billion per year from Acthar, according to CNN.
Powered by WPeMatico